Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 1009 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Can Using a Microwave Cause Cancer? March 25, 2021 Advanced MRI could help to differentiate aggressive and slower growing prostate... February 14, 2022 Can Cancer Prevention Be Better Integrated into Primary Care? June 5, 2023 CancerLand Bookshelf : Loosen July 26, 2021 Load more HOT NEWS FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated... Tattoo Artist Helps Breast Cancer Survivors Cover Their Port Scars Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy... Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in...
